Predictive Ability of Serum IL-27 Level for Assessing Activity of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis by 박용범 et al.
Research Article
Predictive Ability of Serum IL-27 Level for Assessing Activity of
Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
Taejun Yoon,1 Sung Soo Ahn,2 Jung Yoo Pyo,2 Lucy Eunju Lee,2 Jason Jungsik Song,2,3
Yong-Beom Park,2,3 and Sang-Won Lee 2,3
1Department of Medical Science, BK21 Plus Project, Yonsei University College of Medicine, Seoul, Republic of Korea
2Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea
3Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea
Correspondence should be addressed to Sang-Won Lee; sangwonlee@yuhs.ac
Received 17 December 2020; Revised 31 May 2021; Accepted 8 July 2021; Published 19 July 2021
Academic Editor: Vera L. Petricevich
Copyright © 2021 Taejun Yoon et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Serum interleukin- (IL-) 27 level has been reported to increase in patients with several autoimmune diseases; however, its
significance in patients with antineutrophil cytoplasmic antibody- (ANCA-) associated vasculitis (AAV) is unknown. In this
study, we investigated the associations between serum IL-27, laboratory features, and activity of AAV and evaluate the
predictive ability of serum IL-27 level for disease activity. This study included 77 AAV patients, and we collected clinical and
laboratory data at blood sampling. Inflammation-related variables included white blood cell, neutrophil, lymphocyte and platelet
counts, serum albumin, erythrocyte sedimentation rate, and C-reactive protein levels. Serum IL-27 and IL-18 levels were
measured from stored sera using Human Magnetic Luminex® assay. High disease activity of AAV was defined as the highest
tertile of Birmingham vasculitis activity score (BVAS) (≥11). The mean age of the enrolled patients was 59.9 years, and 38
(49.4%) were diagnosed as microscopic polyangiitis. In the multivariable analysis, serum albumin (β = −0:419) and serum IL-27
level (β = 0:221) were significantly associated with BVAS. Furthermore, patients with renal manifestation exhibited higher
serum IL-27 (mean 308.7 pg/mL vs. 105.8 pg/mL) and IL-18 levels (mean 376.7 pg/mL vs. 270.4 pg/mL) than those without. On
applying the optimal cut-off of serum IL-27 level for predicting high activity, AAV patients with serum IL − 27 level ≥ 300:8
pg/mL had a significantly higher risk for having high disease activity than those with serum IL − 27 level < 300:8 pg/mL (relative
risk 3.380, 95% confidence interval 1.223, 9.345, P = 0:016). These results suggest that serum IL-27 level is associated with the
cross-sectional activity and the presence of renal manifestation and could be used to predict high disease activity in patients
with AAV.
1. Introduction
Interleukin- (IL-) 27 is a member of the IL-6/IL-12 family of
cytokines mainly produced by antigen-presenting cells such
as dendritic cells, monocytes, and macrophages and is con-
sisted of two subunits, Epstein-Barr virus-induced gene 3
and p28 [1]. The role of IL-27 in mediating inflammatory
and autoimmune processes is still controversial but largely
considered to be proinflammatory [2]. Importantly, IL-27
induces the proliferation of T and B cells, which can drive
the inflammatory response through enhancement of acquired
immunity [1, 3].With regard to T follicular helper (TFH) cells,
IL-27 improves its function and increases the production of
IL-21, an autocrine cytokine that maintains and stabilises the
function of TFH cells. In addition, activated TFH cells pro-
mote the production of immunoglobulins by B cells and accel-
erate class switching of immunoglobulins closely related to
inflammatory or autoimmune diseases [4]. Meanwhile, IL-27
stimulates the differentiation of TH17 cells and develops their
function by augmenting the production of IL-23, IL-17, IL-6,
and IL-1β to sustain the altered immune response [5, 6].
Accordingly, previous studies that investigated serum IL-27
levels in autoimmune diseases reported that serum IL-27 is
increased in patients with rheumatoid arthritis, systemic lupus
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erythematosus, and systemic sclerosis compared to those in
healthy subjects [7–9].
Currently, systemic vasculitides are classified according
to the size of the invading vessels and the pathologic find-
ings. Among them, small vascular vasculitis (SVV) is divided
into immune complex SVV and antineutrophil cytoplasmic
antibody- (ANCA-) associated vasculitis (AAV) based on
the presence of immune complex deposits. AAV primarily
involves the capillaries, arterioles, and venules and occasion-
ally affects arteries, which shows a critical histological feature
of necrotising vasculitis with few or no immune complex
deposits [10]. AAV is differentiated into three subtypes
including microscopic polyangiitis (MPA), granulomatosis
with polyangiitis (GPA), and eosinophilic granulomatosis
with polyangiitis (EGPA) according to clinical features, lab-
oratory results, and histological findings [10, 11]. While it
has been reported that AAV is a rare disorder with an esti-
mated incidence and prevalence of 1.2-3.3/100,000 and 4.6-
42.1/100,000 [12], recent studies indicate that its occurrence
is rising owing to the advances in the understanding of dis-
ease and improvements in diagnostic tests. Of note, given
that it is associated with increased risk of mortality and mor-
bidity especially in the presence of increased disease activity,
persistent interests have been present in identifying labora-
tory markers that could aid in assessing the disease status
of AAV.
Although it has not been described in the literature
whether IL-27 is directly linked with the pathophysiology of
AAV, there is an increasing body of evidence suggesting that
IL-27 may be associated with heightened inflammation in
AAV. First, in the pathogenesis of AAV, IL-23 and IL-17
are cytokines that could prime neutrophils, as well as initiate
and amplify the production of ANCA by B cells. Further-
more, they activate immune cells including T cells, B cells,
and macrophages and accelerate the complement pathway,
resulting in vascular damage [13, 14]. On the other hand, cir-
culating TFH cells were reported to be significantly increased
in AAV or GPA patients compared to healthy controls [15,
16]. Furthermore, circulating IL-21, which plays an impor-
tant role in activating TFH cells, was also reported to be
higher in AAV or GPA patients than in healthy controls
[17], and we previously demonstrated that serum IL-21-
positive AAV patients exhibited a higher cross-sectional Bir-
mingham vasculitis activity score (BVAS) than serum IL-21-
negative AAV patients [18].
Taking into consideration that IL-27 is considered to be
an upstream regulator that could influence in the differentia-
tion and function of TFH, TH17, and B cells, it may be pos-
sible that serum IL-27 level may be relevant to the disease
severity of AAV. Of note, a previous study by Shen et al. dem-
onstrated that serum IL-27 level was increased in Behçet’s
disease—which is a variable vessel vasculitis—with active
ocular inflammation [19]. However, to the best of our knowl-
edge, no study has been performed to investigate the signifi-
cance of serum IL-27 level in patients with AAV. Hence, the
aim of the present study was to investigate (i) whether there
are associations between serum IL-27, laboratory features,
and activity and (ii) evaluate the predictive ability of serum
IL-27 level for the disease activity of AAV.
2. Materials and Methods
2.1. Patient Selection and Severance Hospital ANCA-
Associated VasculitidEs (SHAVE) Cohort. This study was
performed by using the blood samples and data of 77 patients
who were enrolled in the SHAVE cohort. The SHAVE cohort
is a prospective observational cohort in Severance Hospital of
patients with MPA, GPA, and EGPA: patients were classified
as disease subtypes of AAV according to the 2007 European
Medicines Agency (EMA) algorithm and the 2012 revised
International Chapel Hill Consensus Conference Nomencla-
ture of Vasculitides [10, 11]. In our cohort, whole blood is
drawn after obtaining patient consent and sera is immedi-
ately isolated from whole blood and stored at -80°C. On the
same visit day, routine inflammation-related laboratory tests
and AAV-specific indices of BVAS (version 3) and five-factor
score (FFS) are also assessed to evaluate disease activity and
prognosis [20, 21]. Furthermore, blood collection and assess-
ment of laboratory and clinical data are regularly performed
on every three to six months’ interval. As indicated in the
entry requirement of the 2007 EMA algorithm, we excluded
subjects with concomitant serious infections, malignancies,
or secondary vasculitis other than AAV, which were identi-
fied using the 10th revised International Classification Dis-
eases. This study was approved by the Institutional Review
Board (IRB) of Severance Hospital (4-2016-0901), and writ-
ten informed consent was obtained from all of the patients.
2.2. Clinical and Laboratory Data. All clinical and laboratory
data were used at the period when the collection of sera was
done. Age and sex were included as demographic data, and
disease duration, AAV subtype, and ANCA positivity at the
time of blood sampling were reviewed. Of 77 patients, 40
(51.9%) provided whole blood within one month of AAV
diagnosis and were considered newly diagnosed AAV. In
addition, the presence of clinical manifestations was evalu-
ated based on the subcategories comprising BVAS version 3
[20]. Inflammation-related variables consisted of the white
blood cell (WBC), neutrophil, lymphocyte and platelet
counts, serum albumin, erythrocyte sedimentation rate
(ESR), and C-reactive protein (CRP) levels. Immunosuppres-
sive drugs that the patients are currently on prescription were
identified using the Korean Drug Utilisation Review system.
Serum IL-27 and IL-18 levels in stored sera were measured
using the Human Magnetic Luminex® assay (R&D Systems,
USA) according to the manufacturer’s instructions.
2.3. Measurement of ANCA Positivity. ANCA positivity was
interpreted according to the revised 2017 international con-
sensus on testing of ANCAs in GPA and MPA [22]. We used
immunoassays as the primary screening method for ANCA.
Myeloperoxidase- (MPO-) ANCA and proteinase 3- (PR3-)
ANCA were measured using the novel anchor-coated highly
sensitive Phadia ELiA (Thermo Fisher Scientific/Phadia,
Freiburg, Germany) and the Phadia250 analyser. However,
when patients were found to be negative for ANCA by an
antigen-specific assay but positive by an indirect immunoflu-
orescence assay, they were also considered to be MPO-
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ANCA or PR3-ANCA positive based on the discretion of
treating physician [23].
2.4. Statistical Analyses. Statistical analyses were performed
using the SPSS software (version 25 for Windows; IBM Corp.,
Armonk, NY, USA). Continuous variables are expressed as
mean ± standard deviation, whereas categorical variables are
expressed as numbers (percentages). The correlation coeffi-
cient (r) between the two variables was obtained by the Pear-
son correlation analysis. The standardised correlation
coefficient (β) was obtained by the multivariable linear
regression analysis using variables with statistical significance
in the univariable analysis. Significant differences between
continuous variables were determined using the Student t
-test, while the chi-square test or Fisher’s exact test was car-
ried out for the comparison of categorical variables. Patients
were stratified into three groups based on the tertile of BVAS,
and we defined the lower limit of the highest tertile as the cut-
off for high activity of AAV (BVAS ≥ 11). The optimal cut-off
of serum IL-27 level for high activity of AAV was determined
using the receiver operator characteristic (ROC) curve analy-
sis. The relative risk (RR) of the cut-off of serum IL-27 for
high activity of AAV was analysed using contingency tables
and the chi-square test. Two-tailed P values of less than
0.05 were considered statistically significant.
3. Results
3.1. Clinical Characteristics of Patients. The mean age and the
disease duration of the patients enrolled were 59.9 years and
18.2 months, respectively. Among the 77 patients, 44 (57.1%)
and 33 (42.9%) of the patients were female and male, respec-
tively. The diagnosis of MPA (49.4%), followed by GPA
(31.2%), and EGPA (19.5%), was the most common subtypes
of AAV. In addition, ANCA positivity was found in 55 of the
77 patients, and the mean BVAS and FFS were assessed as
9.8 and 1.3. Clinical manifestation of pulmonary manifesta-
tion (58.4%) and renal manifestation (53.2%) were the most
common in the patients. The mean ESR and CRP were mea-
sured as 42.9mm/h and 20.0mg/L, and the mean levels of
serum IL-27 and IL-18 were 213.7 pg/mL and 327.0 pg/mL,
respectively (Table 1). When the patients were divided
according to sex, renal manifestation was found to be more
frequent and serum IL-18 level was higher in male; however,
no other difference was noted between the other variables
investigated.
3.2. Linear Regression Analysis with Cross-Sectional BVAS. A
linear regression analysis was performed to evaluate the rela-
tionship between inflammation-related variables, IL-27, IL-
18, and BVAS. In the univariable linear regression analysis,
all variables except for lymphocyte count and serum IL-18
level were significantly correlated with the cross-sectional
BVAS. In the multivariable analysis, both serum albumin
(β = −0:419; 95% confidence interval (CI) -7.410, -1.635;
P = 0:003) and serum IL-27 level (β=0.221; 95% CI 0.001,
0.015; P = 0:025) were revealed to be related to BVAS
(Table 2).
3.3. Relationship between Inflammation-Related Variables and
Serum IL-18 and Serum IL-27 Levels. Among inflammation-
related variables and serum IL-18 level, only serum albumin
(r = −0:384, P = 0:001) and serum IL-18 level (r = 0:478,
P < 0:001) were significantly correlated with serum IL-27
level (Table 3).
3.4. Comparison of Serum IL-27 and IL-18 Levels Based on the
Presence and Absence of Clinical Manifestations. Upon com-
paring serum IL-27 and IL-18 levels according to the presence
of each clinical manifestation, only renal manifestations sig-
nificantly differed. Serum IL-27 (mean 308.7 pg/mL vs.
105.8 pg/mL, P < 0:001) and IL-18 (mean 376.7 pg/mL vs.
270.4 pg/mL, P = 0:003) levels in patients with renal manifes-
tation were significantly higher than those in patients with-
out renal manifestation (Table 4).
3.5. The Optimal Cut-Off of Serum IL-27 Level for High
Activity of AAV. Using the ROC curve, the optimal cut-off
of serum IL-27 level for estimating high activity of AAV
was set as 300.8 pg/mL, with a sensitivity and specificity of
50.0% and 79.6% (area 0.641; 95% CI 0.509, 0.773; P =
0:040) (Figure 1(a)).
Next, when AAV patients were divided into two groups
based on the serum IL-27 level of 300.8 pg/mL, 23 of 77
(29.9%) patients were categorized into the group with serum
IL-27 level ≥ 300:8pg/mL. High activity of AAV was identi-
fied more frequently in AAV patients with serum IL-27
level ≥ 300:8pg/mL than those with serum IL-27 level <
300:8pg/mL (56.5% vs. 27.8%, P = 0:016). Moreover, the risk
of having high disease activity was significantly higher in
patients with serum IL-27 level ≥ 300:8pg/mL compared to
those without (RR 3.380, 95% CI 1.225, 9.345) (Figure 1(b)).
4. Discussion
In this study, we investigated the predictive ability of serum
IL-27 level for the activity of AAV and four novel findings
were found. First, serum IL-27 level was significantly associ-
ated with BVAS and independently predicted the cross-
sectional activity of AAV. Second, serum IL-27 level was neg-
atively correlated with serum albumin and positively corre-
lated with serum IL-18 level. Third, patients with renal
manifestation exhibited higher serum IL-27 and IL-18 levels
than those without. Fourth, AAV patients with serum IL-27
level ≥ 300:8pg/mL had a significantly higher risk for high
activity of AAV than those with serum IL-27 level < 300:8
pg/mL (RR 3.380). Therefore, we suggest that serum IL-27
level may be a useful biomarker for predicting the cross-
sectional activity of AAV.
Among the versatile function of IL-27 in influencing the
adaptive immune system [24], two different functions of IL-
27 may be taken into account for explaining the dysregulated
immune response in AAV. First, IL-27 enhances the produc-
tion of immunoglobulin in B cells by stimulating and activat-
ing TFH cells in the germinal centre [4]. Second, IL-27 is
involved in the production of cytokines responsible for prim-
ing neutrophils; thus, increased IL-27 may indirectly facili-
tate the binding of autoantigens on the cell surface of
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neutrophils and circulating ANCAs. Subsequently, neutro-
phils activated by ANCAs could initiate vascular inflam-
mation, and autoreactive B cells are responsible for the
sustained ANCA production [13, 14]. For these reasons, we
hypothesized that serum IL-27 level may have a positive
impact in perpetuating inflammation in AAV. When we
compared serum IL-27 levels between patients with and
without MPO-ANCA (or P-ANCA) and PR3-ANCA (C-
ANCA), it was found that patients with MPO-ANCA (or
P-ANCA) exhibited a significantly higher serum IL-27 level
than those who did not (mean 249.9 pg/mL vs. 148.8 pg/mL,
P = 0:037). However, the presence of PR3-ANCA (or C-
ANCA) did not affect serum IL-27 level, which may in part,
suggest that IL-27 could contribute to the inflammation in
AAV through both the ANCA-dependent and ANCA-
independent pathways.
In this study, we analysed IL-18 level as well as IL-27,
because IL-27 has also shown to regulate immune response
via IL-18 and its binding protein (BP) [25, 26]. Our results
demonstrated that serum IL-27 level was highly correlated
Table 1: Characteristics of 77 patients with AAV.
Variables Total (n = 77) Female (n = 44) Male (n = 33) P value
Demographic data
Age (years) 59.9 (14.5) 59.7 (14.5) 60.1 (14.7) 0.891
Disease duration (months) 18.2 (37.5) 17.1 (30.3) 19.6 (45.9) 0.785
AAV subtypes (N , (%))
MPA 38 (49.4) 22 (50.0) 16 (48.5) 0.896
GPA 24 (31.2) 12 (27.3) 12 (36.4) 0.397
EGPA 15 (19.5) 10 (22.7) 5 (15.2) 0.409
ANCA positivity (N , (%))
MPO-ANCA (or P-ANCA) positive 49 (63.6) 29 (65.9) 20 (60.6) 0.634
PR3-ANCA (or C-ANCA) positive 9 (11.7) 6 (13.6) 3 (9.1) 0.725
Both ANCA positive 3 (3.9) 2 (4.5) 1 (3.0) 0.999
ANCA negative 22 (28.6) 11 (25.0) 11 (33.3) 0.426
AAV-specific indices
BVAS 9.8 (7.6) 8.9 (7.4) 11.0 (7.8) 0.228
FFS 1.3 (0.9) 1.2 (0.9) 1.5 (0.9) 0.161
Clinical manifestations (N , (%))
General manifestation 28 (36.4) 17 (38.6) 11 (33.) 0.634
Cutaneous manifestation 7 (9.1) 4 (9.1) 3 (9.1) 0.999
Mucous and ocular manifestation 3 (3.9) 3 (6.8) 0 (0.0) 0.256
Otorhinolaryngologic manifestation 34 (44.2) 23 (52.3) 11 (33.3) 0.100
Pulmonary manifestation 45 (58.4) 24 (54.5) 21 (63.6) 0.426
Cardiovascular manifestation 4 (5.2) 2 (4.5) 2 (6.1) 0.999
Gastrointestinal manifestation 1 (1.3) 1 (2.3) 0 (0.0) 0.999
Renal manifestation 41 (53.2) 18 (40.9) 23 (69.7) 0.013
Nervous systemic manifestation 21 (27.3) 14 (31.8) 7 (21.2) 0.304
Inflammation-related variables
WBC count (/mm3) 8,646.8 (4,285.0) 8,380.5 (4,602.8) 9,001.8 (3,861.7) 0.532
Neutrophil count (/mm3) 6,177.9 (3,424.8) 5,929.5 (3,485.0) 6,509.1 (3,367.2) 0.466
Lymphocyte count (/mm3) 1,503.6 (763.0) 1,442.5 (717.0) 1,585.2 (824.4) 0.421
PLT count (×1,000/mm3) 303.5 (144.4) 293.9 (147.8) 316.4 (140.9) 0.502
Serum albumin (mg/dL) 3.7 (0.7) 3.8 (0.6) 3.6 (0.8) 0.180
ESR (mm/h) 42.9 (36.3) 44.0 (41.0) 41.5 (29.4) 0.763
CRP (mg/L) 20.0 (40.5) 21.6 (42.7) 17.9 (37.9) 0.697
Serum cytokines
IL-27 (pg/mL) 213.7 (214.7) 193.2 (217.2) 241.3 (211.3) 0.333
IL-18 (pg/mL) 327.0 (160.8) 291.0 (143.5) 375.1 (172.0) 0.022
Values are expressed as a mean ± standard deviation or N (%). ANCA: antineutrophil cytoplasmic antibody; AAV: ANCA-associated vasculitis; MPA:
microscopic polyangiitis; GPA: granulomatosis with polyangiitis; EGPA: eosinophilic granulomatosis with polyangiitis; MPO: myeloperoxidase; P:
perinuclear; PR3: proteinase 3; C: cytoplasmic; BVAS: Birmingham vasculitis activity score; FFS: five-factor score; WBC: white blood cell; PLT: platelet; ESR:
erythrocyte sedimentation rate; CRP: C-reactive protein; IL: interleukin.
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with serum IL-18 level; however, serum IL-18 level did not
correlate with BVAS different from serum IL-27 level.
Although there was a discrepancy between predictions of
the cross-sectional activity of AAV using serum IL-27 level
and serum IL-18 level, both serum IL-27 and serum IL-18
levels were significantly associated with renal manifestation
(Table 4). Accordingly, we also analysed the correlation of
serum IL-27 level and serum IL-18 level with the total score
of each clinical item of BVAS. Serum IL-27 and IL-18 levels
were significantly correlated with only the total score of renal
manifestation among the nine items (r = 0:514, P < 0:001
and r = 0:256, P = 0:025, respectively) (Table 5). In contrast
to IL-18BP, which is an inhibitor of IL-18 activity, IL-18 is
reported to strengthen neutrophil priming and accelerates
the renal progression of AAV [27, 28]. Therefore, IL-18 could
be associated with renal involvement of AAV although IL-18
could not independently predict the cross-sectional activity
of AAV.
Since BVAS is a composite measure comprising a wide
range of clinical, laboratory, and radiological items, it has
been considered the most reliable tool to predict the cross-
sectional activity of AAV [20, 29]. Nevertheless, in actual
clinical practice, a substantial burden of the time is required
to accurately measure many items consisting BVAS. There-
fore, the discovery of a biomarker to predict the cross-
sectional activity of AAV in place of BVAS is expected to
have high clinical utility. Our results indicate that measuring
serum IL-27 level could have clinical implications in the
management of AAV. Notably, the clinical efficacy of serum
IL-27 levels in predicting the cross-sectional activity of AAV
was further investigated by dividing patients into two groups
according to the diagnosis time to exclude the influence of
disease duration in evaluating the relationship between IL-
27 and BVAS. In 40 patients with newly (within one month)
diagnosed AAV, serum albumin (r = −0:488), serum IL-27
level (r = 0:420), and serum IL-18 level (r = 0:431) were sig-
nificantly correlated with the cross-sectional BVAS. Mean-
while, in 37 patients with previously diagnosed AAV at the
time of blood sampling, WBC count (r = 0:354), neutrophil
count (r = 0:472), and serum IL-27 level (r = 0:367) were sig-
nificantly correlated with the cross-sectional BVAS (Table 6).
The results were different between the two groups, but only
serum IL-27 level consistently showed a significant correla-
tion with the cross-sectional activity of AAV. This suggests
that serum IL-27 level could predict the cross-sectional
BVAS regardless of the time of diagnosis when performing
the test. Since serum IL-18 level showed a significant correla-
tion with the cross-sectional BVAS only in newly diagnosed
patients, it is expected that it can be used as a biomarker to
predict BVAS at diagnosis, which should be investigated in
depth by future studies.
The advantage of our study is that this study demon-
strated for the first time that serum IL-27 level could predict
the cross-sectional activity of AAV, and in particular, it
proved its role as a biomarker regardless of the time of
diagnosis. However, we acknowledge that our study pos-
sesses several limitations. This study included a relatively
small number of patients as it was a single-centre study
and did not include healthy controls or a validation cohort,
which may reduce its clinical significance. However, we
believe that it has clinical implications in that it is the first
to discover the predictive ability of serum IL-27 level for
the cross-sectional activity of AAV as a pilot study. In the
near future, studies that include a larger number of patients
and controls are especially warranted providing reliable evi-
dence regarding the clinical relevance of serum IL-27 level
in patients with AAV.
Table 2: Linear regression analysis of inflammation-related variables and serum IL-27 and IL-18 levels with the cross-sectional BVAS.
Variables
Univariable Multivariable
Beta∗ 95% CI P value Beta∗ 95% CI P value
WBC count 0.370 0.277, 1.033 0.001 -0.167 -1.172, 0.580 0.503
Neutrophil count 0.477 0.609, 1.504 <0.001 0.381 -0.166, 1.853 0.100
Lymphocyte count -0.160 -3.845, 0.667 0.165
PLT count 0.304 0.004, 0.027 0.007 0.124 -0.008, 0.021 0.368
Serum albumin -0.620 -8.647, -4.748 <0.001 -0.419 -7.410, -1.635 0.003
ESR 0.388 0.037, 0.125 <0.001 0.168 -0.022, 0.092 0.225
CRP 0.359 0.027, 0.107 0.001 -0.234 -0.098, 0.010 0.112
IL-27 0.393 0.006, 0.021 <0.001 0.221 0.001, 0.015 0.025
IL-18 0.158 -0.003, 0.018 0.170
IL: interleukin; BVAS: Birmingham vasculitis activity score; WBC: white blood cell; PLT: platelet; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.
∗Beta: standardised correlation coefficient.
Table 3: Correlation of inflammation-related variables and serum
IL-18 level with serum IL-27 level.
Variables Correlation coefficient (r) P value
WBC count 0.037 0.748
Neutrophil count 0.120 0.300
Lymphocyte count -0.127 0.270
PLT count -0.056 0.629




IL: interleukin; WBC: white blood cell; PLT: platelet; ESR: erythrocyte
sedimentation rate; CRP: C-reactive protein.
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Absence Presence Absence Presence
General manifestation 196.7 (191.4) 243.8 (251.2) 0.357 327.5 (167.5) 326.2 (151.4) 0.975
Cutaneous manifestation 213.2 (210.6) 220.1 (271.0) 0.936 323.0 (158.8) 366.9 (188.7) 0.496
Mucous and ocular manifestation∗ N/A N/A N/A N/A N/A N/A
Otorhinolaryngologic manifestation 214.0 (201.1) 213.6 (233.8) 0.995 344.8 (185.0) 304.6 (122.7) 0.257
Pulmonary manifestation 214.5 (155.5) 213.3 (250.1) 0.980 325.3 (173.3) 328.2 (153.3) 0.938
Cardiovascular manifestation 214.3 (218.5) 204.8 (145.5) 0.932 326.3 (164.4) 339.8 (77.7) 0.872
Gastrointestinal manifestation∗∗ N/A N/A N/A N/A N/A N/A
Renal manifestation 105.8 (163.5) 308.7 (210.8) <0.001 270.4 (116.8) 376.7 (178.3) 0.003
Nervous systemic manifestation 222.5 (188.5) 190.6 (276.8) 0.630 337.2 (172.8) 299.8 (123.0) 0.367
Values are expressed as amean ± standard deviation. IL: interleukin; BVAS: Birmingham vasculitis activity score; N/A: not applicable. ∗Since only three patients
presented mucous and ocular manifestation, statistical analysis is not reliable. ∗∗Since only one patients presented gastrointestinal manifestation, statistical












































Figure 1: Cut-off of serum IL-27 level for high activity of AAV and relative risk. (a) The optimal cut-off of the serum IL-27 level for predicting
high activity of AAV was set as 300.8 pg/mL. (b) AAV patients with serum IL-27 level ≥ 300:8 pg/mL had a significantly higher risk of having
high activity than those without. IL: interleukin; ANCA: antineutrophil cytoplasmic antibody; AAV: ANCA-associated vasculitis; RR: relative
risk.
Table 5: Correlation of serum IL-27 level and serum IL-18 level with the total score of each clinical item of BVAS.
Serum IL-27 level Serum 18 level
Correlation coefficient (r) P value Correlation coefficient (r) P value
General manifestation 0.084 0.468 0.011 0.924
Cutaneous manifestation -0.062 0.590 0.043 0.707
Mucous and ocular manifestation 0.192 0.094 -0.014 0.901
Otorhinolaryngologic manifestation 0.088 0.445 -0.122 0.292
Pulmonary manifestation 0.104 0.369 0.059 0.611
Cardiovascular manifestation -0.024 0.836 0.034 0.771
Gastrointestinal manifestation -0.115 0.320 -0.086 0.458
Renal manifestation 0.514 <0.001 0.256 0.025
Nervous systemic manifestation -0.002 0.987 -0.007 0.949
IL: interleukin; BVAS: Birmingham vasculitis activity score.
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5. Conclusions
In conclusion, serum IL-27 level was associated with the
cross-sectional activity of AAV and the presence of renal
manifestation and was predictive of high disease activity in
patients with AAV, indicating that it could have clinical
implications in patients with AAV.
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